NCT03946592

Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat

A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 148 (actual)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat

Detailed description

DWJ211 is a injectable drug for improvement in the appearance of moderate to severe submental fat (SMF)

Conditions

• Submental Fat

Interventions

Type	Name	Description
DRUG	Normal saline	Inject the Drug into submental fat via subcutaneous
DRUG	DWJ211	Inject the Drug into submental fat via subcutaneous

Timeline

• Start date: 2019-05-15
• Primary completion: 2020-07-02
• Completion: 2020-07-02
• First posted: 2019-05-10
• Last updated: 2024-04-04

Locations

1 site across 1 country: South Korea